NDC codes

FDA NDC Directory
Product NDC (as listed)73190-084Labeler and product segments. Claims need a package NDC.
Product NDC at billing width73190-0084Add the package segment from the table below.
Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC11-digit (billing)PackageCopy
73190-084-0173190008401100 TABLET in 1 BOTTLE (73190-084-01)Marketed from Jun 15, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary)
Methimazole
Generic name (nonproprietary)
methimazole
Active ingredients
Methimazole — 5 mg/1
Dosage form
Tablet
Route
Oral
Labeler
AvKARE
Product type
Prescription drug
Marketing category
ANDA — Abbreviated New Drug Application (generic)Application ANDA 040547
Marketing start
Listing expires
Other FDA classes
Thyroid Hormone Synthesis Inhibitors (Mechanism)
Identifiers
Product ID 73190-084_5453cbc0-5baf-f126-e063-6394a90a7477SPL ID 5453cbc0-5baf-f126-e063-6394a90a7477SPL set ID 545381b6-e9e9-de1e-e063-6294a90a9a97RxCUI 197941, 197942UNII 554Z48XN5EUPC 0373190084014, 0373190085011
Pharmacologic class
Thyroid Hormone Synthesis Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N473190008401 followed by a unit qualifier and the quantity

Package 73190-0084-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective .

Indications (excerpt from the label)

INDICATIONS AND USAGE Methimazole tablets are indicated: In patients with Graves’ disease with hyperthyroidism or toxic multinodular goiter for whom surgery or radioactive iodine therapy is not an appropriate treatment option. To ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 040547

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 040547
ProductStrengthForm · routeLabelerProduct NDC
MethimazoleMethimazole 5 mg/1TabletOralUpsher-Smith Laboratories, LLC0832-6072
MethimazoleMethimazole 10 mg/1TabletOralAvKARE73190-085
MethimazoleMethimazole 10 mg/1TabletOralUpsher-Smith Laboratories, LLC0832-6073
MethimazoleMethimazole 5 mg/1TabletOralAiPing Pharmaceutical, Inc.11788-011
MethimazoleMethimazole 10 mg/1TabletOralAiPing Pharmaceutical, Inc.11788-012

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free Med-Code account to keep looking up NDCs, J-codes and drugs.

Create a free accountLog in